Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 48, n° 4
pages 578-583 (avril 2003)
Doi : 10.1067/mjd.2003.144
Mizolastine in primary acquired cold urticaria

Louis Dubertret, MD a, Catherine Pecquet, MD b, Margarita Murrieta-Aguttes, MD c, Francisque Leynadier, MD b
a Hôpital Saint-Louis Paris, France 
b Hôpital Tenon Paris, France 
c Sanofi ~ Synthélabo. Paris, France 


Background: Treatment of primary acquired cold urticaria (CU) is quite difficult because of variable clinical effectiveness and side effects of classic antihistamines. Objective: The objective of the study was to assess the efficacy and safety of mizolastine, an antihistaminic with antiallergic properties, versus placebo in primary acquired CU. Methods: This study was a phase II, multicenter, randomized, double-blind, crossover, placebo-controlled study of mizolastine (10 mg, once daily) versus placebo in 28 patients with primary acquired CU. Efficacy was measured by the cold-stimulation time test, the wheal response, and pruritus intensity after an ice-cube test. Results: Mizolastine delayed the cold-induced wheal reaction, reduced wheal response at 3 and 10 minutes, and reduced pruritus intensity. Statistically significant differences were observed versus placebo for the cold-stimulation time test, wheal response at 3 and 10 minutes, and pruritus intensity (P = .006, .015, .009, and .005, respectively). No clinically relevant adverse events were reported. Conclusions: Mizolastine (10 mg, once daily) was shown to be superior to placebo for both delaying and reducing the cold-induced wheal reaction without significant adverse events. Results suggest that mizolastine may be effective in the treatment of CU. (J Am Acad Dermatol 2003;48:578-83.)

The full text of this article is available in PDF format.

 Supported by Sanofi-Synthélabo.
 Conflict of interest: None identified.
 Reprint requests: Margarita Murrieta-Aguttes, MD, Sanofi ~ Synthélabo, 174, Avenue de France, 75635 Paris Cedex 13, France.
 0190-9622/2003/$30.00 + 0

© 2003  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@